RareDiseasesNews.net

Rare diseases Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Gastrobase.it

Infants with tyrosinemia type 1: phenylalanine supplementation regimen require investigation


Tyrosinemia type 1 ( HT1 ) is an inborn error of tyrosine catabolism caused by fumarylacetoacetase deficiency. Biochemically, this results in accumulation of toxic metabolites including succinylacetone.

Clinically, tyrosinemia type 1 is characterized by severe liver, kidney, and neurological problems. Treatment with Nitisinone ( NTBC; Orfadin ) and dietary restriction of tyrosine and phenylalanine have strongly improved outcome, but impaired neurocognitive development has been reported.
Whether impaired neurocognitive outcome results from high blood tyrosine or low blood phenylalanine concentrations is currently unknown.

In a report, two tyrosinemia type 1 newborns, diagnosed by neonatal screening, are presented.

The first patient showed low phenylalanine concentrations, growth retardation, neurological impairments, and skin problems, clearly improving after institution of phenylalanine supplementation ( approximately 30 mg/kg/day ) at age 6 months, while both blood phenylalanine and tyrosine concentrations increased.

In the second patient, phenylalanine supplementation ( approximately 20 mg/kg/day ) was initiated as soon as low phenylalanine concentrations were observed at age 19 days. On this regimen, blood phenylalanine concentrations increased, and hypophenylalaninemia was less frequently observed than in the first patient, whereas blood tyrosine concentrations tended to increase. Clinically, no growth, neurological, or skin problems have been observed.

The combination of knowledge obtained from these cases suggests that hypophenylalaninemia rather than hypertyrosinemia during the first months of life may impair neurocognitive development in young HT1 infants.
Phenylalanine supplementation should really be considered in HT1 patients with consistently low blood phenylalanine concentrations during the first months of life.
However, the minimal phenylalanine concentrations acceptable and the optimal phenylalanine supplementation regimen require further investigation. ( Xagena )

van Vliet D et al, JIMD Rep 2015;18:117-124

XagenaMedicine_2014



Indietro